CD6 contributes to cell adhesion/migration both through direct ligand interactions with activated leukocyte cell adhesion molecule (ALCAM) and through the stabilization of cell membrane VLA4

Blockade of CD6 through itolizumab prevents the trans-endothelial migration of effector T cells

Data supports the differentiated mechanism of action of itolizumab

Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, today announced that a poster was presented at IMMUNOLOGY2024, the annual meeting of The American Association of Immunologists. The meetings are taking place at McCormick Place Convention Center in Chicago, Illinois, May 3 – 7.

“Our data demonstrates that CD6 contributes to cell adhesion/migration both through direct ligand interactions with ALCAM and through the stabilization of cell membrane VLA4, and that these functions can be abrogated by itolizumab,” said Dr. Stephen Connelly, chief scientific officer at Equillium. “We previously showed that blockade of CD6 prevents the trans-endothelial migration of effector T cells and this new data further elucidates the molecular mechanism. Moreover, our data continues to demonstrate that increased levels of CD6 facilitate the migration of pathogenic effector T cells into inflamed tissues and that itolizumab can modulate not only their activity, but trafficking too.”

Title: Surface CD6 regulates T cell adhesion and migration through direct ligand interaction and stabilization of VLA4 Lead Author: Valeria Marrocco, Senior Scientist, Equillium, Inc. Presentation Type: Poster Session Poster Number: P713 Abstract ID: 4364 Session Title: Migration and Adhesion in Inflammation, Cancer, and Metabolic Disorders

Key Highlights, Summaries & Conclusions from Presentation:

  • Itolizumab not only blocks the binding of CD6 to ALCAM, but it also induces the stripping of the receptor on the T cells’ membrane in the presence of antigen presenting cells, generating CD6 low T cells.
  • Reduction of CD6 on T cells or blocking of ALCAM on the human umbilical vein endothelial cells (HUVEC), prevents the adhesion of Effector T cells to the endothelial monolayer.
  • Itolizumab treatment significantly reduced the trans-endothelial migration of pathogenic T cells, with high correlation of effector T cells’ migration index with the CD6 levels on the cell surface.
  • Itolizumab treatments reduced the gene expression important for cell motility and downregulated VLA4 integrin levels on the cell surface and the total protein levels.
  • Data identifies a new role of the CD6-ALCAM pathway in adhesion and trans-endothelial migration of effector T cells and demonstrated that CD6 expression at the membrane is required for the expression and stabilization of the integrin VLA4. This suggests a direct role of the CD6-ALCAM pathway and indirect T cell mobility regulation through downregulation of VLA4.

The poster presentation is available on the Presentations page of Equillium’s website under the “Itolizumab MOA” tab.

About Itolizumab

Itolizumab is a clinical-stage, first-in-class anti-CD6 monoclonal antibody that selectively targets the CD6-ALCAM signaling pathway to selectively downregulate pathogenic T effector cells while preserving T regulatory cells critical for maintaining a balanced immune response. This pathway plays a central role in modulating the activity and trafficking of T cells that drive a number of immuno-inflammatory diseases.

About Equillium

Equillium is a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat severe autoimmune and inflammatory disorders with high unmet medical need. The company’s pipeline consists of the following novel first-in-class immunomodulatory assets and product platform targeting immuno-inflammatory pathways. EQ101: a selective tri-specific cytokine inhibitor targeting IL-2, IL-9, and IL-15; currently under evaluation in a Phase 2 proof-of-concept clinical study of patients with alopecia areata being conducted in Australia and New Zealand by Equillium’s Australian subsidiary as the trial sponsor. EQ302: an orally delivered, selective bi-specific cytokine inhibitor targeting IL-15 and IL-21; currently in pre-clinical development. The multi-cytokine platform: generates rationally designed composite peptides that selectively block key cytokines at the shared receptor level targeting pathogenic cytokine redundancies and synergies while preserving non-pathogenic signaling. Itolizumab: a monoclonal antibody that targets the CD6-ALCAM signaling pathway which plays a central role in the modulation of effector T cells; currently under evaluation in a Phase 3 clinical study of patients with acute graft-versus-host disease (aGVHD) and recently completed a Phase 1b clinical study of patients with lupus/lupus nephritis. Equillium acquired rights to itolizumab through an exclusive partnership with Biocon Limited and has entered a strategic partnership with Ono Pharmaceutical Co., Ltd., for the development and commercialization of itolizumab under an option and asset purchase agreement.

For more information, visit www.equilliumbio.com.

Forward Looking Statements

Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as "anticipate", "believe", “could”, “continue”, "expect", "estimate", “may”, "plan", "outlook", “future” and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Because such statements are subject to risks and uncertainties, many of which are outside of Equillium’s control, actual results may differ materially from those expressed or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include: Equillium’s ability to execute its plans and strategies; risks related to performing clinical studies; whether the results from clinical studies will validate and support the safety and efficacy of Equillium’s product candidates. These and other risks and uncertainties are described more fully under the caption "Risk Factors" and elsewhere in Equillium's filings and reports, which may be accessed for free by visiting the Securities and Exchange Commission’s website at www.sec.gov and on Equillium’s website under the heading “Investors.” Investors should take such risks into account and should not rely on forward-looking statements when making investment decisions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Equillium undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as required by law.

Investor & Media Contact Equillium, Inc. Michael Moore Vice President, Investor Relations Officer & Head of Corporate Communications 619-302-4431 ir@equilliumbio.com

Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Nov 2024 a Dic 2024 Clicca qui per i Grafici di Equillium
Grafico Azioni Equillium (NASDAQ:EQ)
Storico
Da Dic 2023 a Dic 2024 Clicca qui per i Grafici di Equillium